Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIKINASDAQ:DOMHNASDAQ:ISPCNASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIKIAIkido Pharma$5.99+12.6%$4.69$3.31▼$11.48$32.86M0.9379,326 shs495,403 shsDOMHDominari$5.87-2.0%$4.63$0.83▼$13.58$85.96M0.591.34 million shs346,532 shsISPCiSpecimen$1.17+2.8%$1.26$1.02▼$11.80$2.92M1.73414,835 shs22,641 shsSBFMSunshine Biopharma$1.35+8.0%$1.68$1.17▼$23.20$3.65M1.35605,176 shs142,352 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIKIAIkido Pharma0.00%+5.83%+62.77%+86.02%+182.77%DOMHDominari0.00%+5.83%+55.99%-2.76%+182.77%ISPCiSpecimen0.00%-10.05%-6.73%-46.83%+374.52%SBFMSunshine Biopharma0.00%-8.39%-7.72%-49.40%+40.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIKIAIkido PharmaN/AN/AN/AN/AN/AN/AN/AN/ADOMHDominari0.8883 of 5 stars0.02.00.00.02.92.50.6ISPCiSpecimen0.8081 of 5 stars0.03.00.00.03.30.80.6SBFMSunshine Biopharma2.9352 of 5 stars3.55.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIKIAIkido Pharma 0.00N/AN/AN/ADOMHDominari 0.00N/AN/AN/AISPCiSpecimen 0.00N/AN/AN/ASBFMSunshine Biopharma 3.00Buy$15.001,011.11% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIKIAIkido Pharma$10K3,285.52N/AN/A$19.27 per share0.31DOMHDominari$18.15M4.74N/AN/A$9.90 per share0.59ISPCiSpecimen$9.29M0.31N/AN/A$21.47 per share0.05SBFMSunshine Biopharma$34.87M0.10N/AN/A$1,651.69 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIKIAIkido Pharma-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/ADOMHDominari-$22.88M-$2.39N/A∞N/A-180.22%-32.89%-29.47%N/AISPCiSpecimen-$11.10M-$18.58N/A∞N/A-91.66%-139.25%-73.97%N/ASBFMSunshine Biopharma-$4.51M-$150.88N/A∞N/A-12.82%-17.89%-14.25%5/19/2025 (Estimated)Latest DOMH, AIKI, SBFM, and ISPC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2025Q4 2024DOMHDominariN/A$0.20N/A$0.20N/A$6.56 million4/14/2025Q4 2024ISPCiSpecimen-$4.00-$6.28-$2.28-$6.28$2.98 million$1.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIKIAIkido PharmaN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AISPCiSpecimenN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIKIAIkido PharmaN/A29.5429.54DOMHDominariN/A10.2510.25ISPCiSpecimenN/A0.740.74SBFMSunshine BiopharmaN/A5.743.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIKIAIkido Pharma10.88%DOMHDominari42.48%ISPCiSpecimen13.62%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipAIKIAIkido Pharma8.60%DOMHDominari32.98%ISPCiSpecimen12.20%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIKIAIkido Pharma45.49 million5.01 millionNot OptionableDOMHDominari414.64 million4.01 millionNot OptionableISPCiSpecimen602.50 million846,000Not OptionableSBFMSunshine Biopharma32.71 million1.22 millionNot OptionableDOMH, AIKI, SBFM, and ISPC HeadlinesRecent News About These CompaniesSunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comSunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comSunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comSunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comSunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deSunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rightsMarch 10, 2025 | markets.businessinsider.comSunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | accessnewswire.comSunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODTJanuary 21, 2025 | accessnewswire.comSunshine Biopharma Announces the Appointment of New Chief Commercial OfficerJanuary 15, 2025 | accesswire.comSunshine Biopharma Announces Novel Inhibitor for Sars CoronavirusDecember 9, 2024 | accesswire.comSunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBCNovember 25, 2024 | pharmabiz.comSunshine Biopharma Launches a New Generic Prescription DrugNovember 22, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDOMH, AIKI, SBFM, and ISPC Company DescriptionsAIkido Pharma NASDAQ:AIKI$5.99 +0.67 (+12.59%) As of 05/9/2025AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Dominari NASDAQ:DOMH$5.87 -0.12 (-2.00%) As of 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.iSpecimen NASDAQ:ISPC$1.17 +0.03 (+2.82%) Closing price 04:00 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Sunshine Biopharma NASDAQ:SBFM$1.35 +0.10 (+8.00%) Closing price 04:00 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
